Efficacy of 24-Week Monotherapy With Acarbose, Metformin, or Placebo in Dietary-Treated NIDDM Patients
- 1 December 1997
- journal article
- research article
- Published by Elsevier in The American Journal of Medicine
- Vol. 103 (6) , 483-490
- https://doi.org/10.1016/s0002-9343(97)00252-0
Abstract
No abstract availableThis publication has 33 references indexed in Scilit:
- A Comparison of Acarbose Versus Metformin as an Adjuvant Therapy in Sulfonylurea-Treated NIDDM PatientsDiabetes Care, 1996
- Metabolic Effects of Metformin in Non-Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1995
- Efficacy of Metformin in Patients with Non-Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1995
- Reduction of Glycosylated Hemoglobin and Postprandial Hyperglycemia by Acarbose in Patients With NIDDM: A placebo-controlled dose-comparison studyDiabetes Care, 1995
- Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitusThe American Journal of Medicine, 1995
- The Efficacy of Acarbose in the Treatment of Patients with Non–Insulin-Dependent Diabetes Mellitus: A Multicenter, Controlled Clinical TrialAnnals of Internal Medicine, 1994
- Therapeutic Comparison of Metformin and Sulfonylurea, Alone and in Various Combinations: A double-blind controlled studyDiabetes Care, 1994
- Efficacy of 24-Week Monotnerapy With Acarbose, Glibenclamide, or Placebo in NIDDM Patients: The Essen StudyDiabetes Care, 1994
- Therapeutic Potentials of Acarbose as First-Line Drug in NIDDM Insufficiently Treated With Diet AloneDiabetes Care, 1991
- AcarboseDrugs, 1988